UBX earnings

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidence interval), but did not meet statistical non-inferiority on the average of weeks 20 and 24, the primary analysis endpoint (met at 88% confidence interval) UBX1325-treated patients had a +5.2 letter gain in visual acuity at 24 weeks and a +5.5 letter gain at 36 weeks UBX1325 was numerically superior to aflibercept at 7 out of 10 time points in a pre-specified population with moderately aggressive disease UNITY to host investor call with retinal expert Robert B. Bhisi

A single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in Best Corrected Visual Acuity (BCVA) of +6.2 ETDRS letters from baseline at 48 weeks Approximately 53% of UBX1325-treated patients did not require any additional injections through 48 weeks Retinal structure, as measured by central subfield thickness (CST), was maintained in UBX1325-treated patients throughout the duration of the study UBX1325 had a favorable safety and tolerability profile with no evidence of intraocular inflammation  UNITY to host investor call with retinal expert Robert B. Bhisitkul, M.D., Ph.D., today, April 24 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., April

UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm UBX1325 maintained visual acuity in patients with ongoing active disease through 24 weeks with less than one letter mean decrease from baseline 52% of UBX1325-treated patients did not require anti-VEGF treatment through 24 weeks Company to share 48-week BEHOLD DME data in April and intends to initiate Phase 2b study in DME in second half of 2023 UNITY to host investor call today, March 27, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company d

A single injection of UBX1325 led to a statistically significant and clinically relevant improvement in Best Corrected Visual Acuity (BCVA) of 7.6 ETDRS letters at 24 weeks compared to sham treatment UBX1325 maintained stabilization of retinal structure, as measured by central subfield thickness (CST) at 24 weeks, as compared to worsening from baseline in sham-treated patients The proportion of rescue-free patients in the UBX1325-treated arm was 59.4% at 6 months after a single injection, as compared to only 37.5% in the sham-treated arm UNITY to host investor call with retinal expert Arshad M. Khanani, M.D., M.A., FASRS, today, November 1, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., No

A single injection of UBX1325 led to a progressive, statistically significant, and clinically meaningful improvement in mean Best Corrected Visual Acuity (BCVA) at 12- and 18-weeks compared to sham treatment UBX1325 treatment also stabilized retinal structure, as measured by central subfield thickness (CST) at 12- and 18-weeks, as compared to worsening in sham-treated patients The treatment effect was seen in a patient population with visual acuity deficits and residual retinal fluid despite frequent and recent anti-VEGF therapy UNITY to host investor call with retinal expert Robert Bhisitkul, M.D., Ph.D., today, August 12, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 12, 2022 (G

Patients with diabetic macular edema in higher dose cohorts showed a mean BCVA gain of approximately 10 ETDRS letters sustained through 24 weeks after a single intravitreal injection Patients with wet age-related macular degeneration showed improvement in visual acuity through 12 weeks supporting initiation of Phase 2 study in AMD UNITY to host investor call with retinal experts Arshad Khanani, M.D., M.A., and Robert Bhisitkul, M.D., Ph.D., today, November 9, 2021 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, tod

Evidence of improvement in vision and retinal structure in patients with DME and AMD sustained through 12 weeks Sustained responses following single treatment with UBX1325 support durability of senolytic therapeutic approach; data builds on previously reported results at 8 weeks Study remains on track with 24-week data expected before the end of the year UNITY to host investor call with retinal expert Robert Bhisitkul, M.D., Ph.D., on October 5, 2021 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced

UNITY management team and Dr. Bhisitkul to discuss initial safety and efficacy data supporting improvements in vision and structure seen in patients treated with a single dose of UBX1325 UNITY to host conference call on July 27, 2021, at 8:00 a.m. PT (11:00 a.m. ET) SOUTH SAN FRANCISCO, Calif., July 23, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host a webcast for investors and analysts on July 27, 2021 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) to discuss clinical data from the Phase 1 study in diabetic macular ede